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Purpose: Calibration of hyperpolarized 13C-MRI is limited by the low signal from 
endogenous carbon-containing molecules and consequently requires 13C-enriched 
external phantoms. This study investigated the feasibility of using either 23Na-MRI 
or 1H-MRI to calibrate the 13C excitation.
Methods: Commercial 13C-coils were used to estimate the transmit gain and center 
frequency for 13C and 23Na resonances. Simulations of the transmit B1 profile of a 
Helmholtz loop were performed. Noise correlation was measured for both nuclei. 
A retrospective analysis of human data assessing the use of the 1H resonance to 
predict [1-13C]pyruvate center frequency was also performed. In vivo experiments 
were undertaken in the lower limbs of 6 pigs following injection of hyperpolarized 
13C-pyruvate.
Results: The difference in center frequencies and transmit gain between tissue 
23Na and [1-13C]pyruvate was reproducible, with a mean scale factor of 1.05179 ± 
0.00001 and 10.4 ± 0.2 dB, respectively. Utilizing the 1H water peak, it was possible  
to retrospectively predict the 13C-pyruvate center frequency with a standard  
deviation of only 11 Hz sufficient for spectral–spatial excitation-based studies.
Conclusion: We demonstrate the feasibility of using the 23Na and 1H resonances to 
calibrate the 13C transmit B1 using commercially available 13C-coils. The method pro-
vides a simple approach for in vivo calibration and could improve clinical workflow.
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1 |  INTRODUCTION
Hyperpolarized 13C MRI is an emerging technique to non-
invasively image cellular metabolism in health and disease: 
the exchange of hyperpolarized 13C-pyruvate to 13C-lactate 
is the most studied in vivo reaction using the technique.1-3 
The recent translation of the technology into human stud-
ies has demonstrated applications for the method in prostate 
and brain tumors as well as the normal heart and brain.4-8 
However, there are a number of challenges to be overcome 
before the technology can be used more routinely. For ex-
ample, calibration of the RF amplifier gain (here referred to 
as RF gain as well as transmit gain (TG), coil voltage, and 
coil reference scale), center frequency (f0), and estimation of 
transmit–receive B1 for 13C can be challenging given the very 
short time window for hyperpolarized 13C imaging following 
a single injection of hyperpolarized 13C  labelled substrate. 
Calibration is usually undertaken prior to the detection of the 
transient hyperpolarized 13C-pyruvate signal in vivo. A num-
ber of solutions to this problem have been proposed, includ-
ing the use of a phantom containing a high concentration of 
13C-enriched molecules for calibration, as well as phantom 
acquisition prior to patient scanning.9 Although these meth-
ods provide an estimation of RF gain for the field of view 
(FOV) containing the phantom, there is no current method to 
establish the transmit B1 field over the whole FOV, which is 
particularly relevant because variations in the delivered flip 
angle are expected throughout the patient. Furthermore, the 
position and composition of the phantom increase the uncer-
tainty of centre frequency estimation.
A selective excitation approach is frequently employed 
to acquire high signal to noise ratio images of the metabolic 
products of [1-13C]pyruvate. Deviations in the flip angle 
across the FOV can introduce significant uncertainty in the 
kinetic parameters that are derived using this spectral–spatial 
imaging approach.10,11 A further challenge is the estimation 
of coil sensitivity maps, which is used to accurately combine 
the images from individual coils. This absence of significant 
signal from natural abundance 13C renders these challenges 
difficult to solve without the use of a phantom. An interesting 
calibrationless approach has been reported that uses the pyru-
vate signal to estimate the sensitivity map for in vivo studies.12
Here, we propose using the endogenous signal derived 
from the 1H and 23Na nuclei as a reference for the 13C imag-
ing: 23Na has a resonant frequency similar to that of 13C at 
clinical field strengths (~1 MHz difference at 3 tesla) with 
a relatively high natural abundance in the body, producing 
the second highest signal on MRI from the nuclei detectable 
in biological tissues. The 1H nucleus is the highest natural 
abundance NMR active signal in the body and thus represents 
a further option to confirm center frequency placement prior 
to 13C acquisition. A number of clinical studies have demon-
strated the biodistribution of sodium using 23Na-MRI in both 
health and disease.13-16 Previous reports have utilized a vari-
able capacitor custom-built RF coil to enable the coil to be 
tuned to both the 13C and 23Na frequency, allowing accurate 
RF gain estimation for rodent studies.17,18 In this study, we 
have expanded on this work to study the use of commercially 
available single tuned 13C coils to acquire transmit B1 and f0 
information from the 23Na resonance using a clinical system 
in large animals, therefore providing the translational leap re-
quired for this technique to be incorporated into routine clin-
ical practice. Furthermore, we have incorporated the use of 
the 1H nucleus to provide further confidence in the estimated 
13C center frequency derived from the 23Na measurements. 
This approach could improve the workflow of hyperpolar-
ized 13C-MRI experiments by removing the reliance on exter-
nal phantoms for the prescan acquisition on clinical systems 
using the data acquired on commercially available coils.
2 |  METHODS
Experiments were performed at 2 different sites (MR 
Research Centre, University of Aarhus, Denmark; Department 
of Radiology, University of Cambridge, UK), which are re-
ferred to as sites A and B, respectively.
Human study: Local ethical approval was obtained for 
this prospective study (NRES Committee East of England, 
Cambridge South, REC number 15/EE/ 0255).
Porcine study: All porcine imaging was undertaken in ac-
cordance with the Danish Animal Welfare Act 2013 follow-
ing an explicit national ethical review process undertaken by 
the Danish Animal Experiments Inspectorate.
2.1 | Phantom and coil setup
Phantom experiments were performed at site A using a 
13C-labeled urea (8 M, Merck, Darmstadt, Germany) vial and 
identical 1 L containers filled with saline at varying concen-
trations (156, 117, 78, 39 mmolL−1). The 13C-urea phantom 
was placed on top of the saline phantom and secured. The re-
ceive coils used in this study were tuned to 13C and included 
a simple loop coil (Rapid Biomedical, Rimpar, Germany) 
and 8-channel paddle coils (GE Healthcare, Waukesha, WI, 
K E Y W O R D S
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USA). The loop coil was placed on top of the 13C-urea phan-
tom, and the paddle coils were placed around the right and 
left side of the saline bottles. A separate 13C-tuned clam-
shell volume coil (Rapid Biomedical, Q unloaded = 270, 
Q loaded = 75, S11 < −150 cB) was used for transmission.19 
Data acquisition was undertaken using a 3 tesla scanner 
(MR750, GE Healthcare). Phantom and coil positioning can 
be seen in Supporting Information Figure S1.
2.2 | RF gain and f0 estimation
Using the phantom setup described above, RF gain and f0 
were assessed using a commercially available pulse-acquire 
sequence (Fidall, GE Healthcare) with 2 off-resonance 
Bloch-Siegert pulses (excitation pulse width = 0.5 ms, rep-
etition time = 2 s, echo time = 0.5 ms, flip angle = 90°).20 
Estimation of RF gain and f0 for 13C and 23Na were performed 
in series. Experiments were repeated in triplicate, with the 
phantom removed and re-sited between each repeat. 1H, 13C, 
and 23Na acquisitions were acquired for all saline concentra-
tions. Scaling factors to convert between the 1H f0, 23Na f0, 
and the 13C f0 were derived from Equations 1 and 2:
where f 1H
0
, f 23Na
0
, and f 13C
0
 are the center frequencies of 1H, 
23Na, and 13C, respectively.
A further correction for the difference in TG between 
23Na and 13C was derived using Equation 3. Because RF gain 
is logarithmically scaled, the subtraction rather than the ratio 
between 13C and 23Na RF gain is used.
where TG23Na and TG13C are the required TG for 23Na and 13C, 
respectively.
The mean scaling factors for frequency and gain were de-
rived by averaging across all experiments.
2.3 | Multinuclear transmit B1 and 
B0 mapping
Carbon-13 and sodium-23 transmit B1 maps were calculated 
using a cylindrical 8 L saline/pyruvate phantom (150 and 
102 mmolL−1 respectively, doped with 80 mL Gadovist to 
shorten the 13C T1 below 1 s; 1H-MRI image shown in 
Supporting Information Figure S2A), a 16-channel receive 
array coil (Rapid Biomedical, Rimpar, Germany), and 
a clamshell transmit coil, and by employing the double 
angle method.21 Acquisition parameters were as follows: 
2D-chemical shift imaging (CSI), slice thickness = 60 mm, 
spectral width = 5000 Hz, spectral resolution = 256 points, 
FOV = 240 mm, matrix = 8 × 8, flip angles = 40 and 80, 13C 
number of averages (NEX) = 32, 23Na NEX = 64, 13C repeti-
tion time = 2.5s, 23Na repetition time = 600 ms, RF pulse = 
partially self-refocusing sinc excitation (1.8 ms, bandwidth 
2289 Hz for 13C) or hard pulse (pulse width = 2 ms, for 23Na), 
23Na echo time = 1.2 ms, and 13C echo time = 1.8 ms. The 
width of the hard pulse is 4 times longer than the default 
(0.5 ms). Because 23Na requires approximately 12 dB more 
power than 13C, the pulse width for 23Na was quadrupled, 
although the amplitude was fixed to remain the same as for 
the default pulse width. Spectral data were zero-filled in 
the time domain to 1024 points, Fourier-transformed, zero-
order–phased, and fit with a Lorentzian function prior to cal-
culation of B0 and B1 maps. All processing was performed in 
MatLab (2018b, MathWorks, Natick, MA).
B0 maps were calculated on a voxel-by-voxel basis by 
finding the center of the pyruvate or sodium resonance rela-
tive to the system center frequency for the inner 6 × 6 voxels 
of the 2D CSI grid. The mean difference in center frequency 
for both resonances was calculated over the phantom. The 
mean difference between 13C and 23Na B0 maps was calcu-
lated for the 6 × 6 grid in Hertz, as well as the mean B0 shift 
across the FOV for each nucleus in Hertz.
The mean B1 ratio, as well as the mean absolute percent-
age difference defined in Equation 4, at and between both 
frequencies was calculated from the inner 6 × 6 voxels of the 
2D CSI grids:
where x and y are the spatial locations of each voxel in the 
6 × 6 CSI grid.
2.4 | Simulations
The B+
1
 distribution of the clamshell volume coil was simu-
lated using the frequency solver within Computer Simulation 
Technology software (CST, CST 2018, Darmstad, Germany). 
The coil consisted of 2 square loops of 300 mm diameter 
placed coaxially with the centers separated by 360 mm. This 
coil design provides a homogenous resonance mode when 
the signal in its 2 loops is shifted 180°. For the analysis in 
this study, it was important to include in the simulation a 
(1)23Na, 13CFrequency scaling factor =
f
23Na
0
f
13C
0
(2)1H, 13CFrequency scaling factor =
f
1H
0
f
13C
0
,
(3)Gain correction = TG23Na−TG13C,
(4)Percentage differencex,y=100
⎛⎜⎜⎝
B
13C
1(x,y)
−B
23Na
1(x,y)
B
23Na
1(x,y)
⎞⎟⎟⎠ ,
4 |   GRIST eT al.
real implementation of the phase shifter used to create the 
homogenous mode because it is also frequency-dependent. 
For that purpose, a lumped-element 180° hybrid circuit22 
tuned to the 13C frequency was included in the simulation 
using the circuit cosimulation feature within the software. 
A schematic of the whole simulation setup is shown in 
Figure 1, including the matching networks (lattice baluns) 
needed between the 180° hybrid and the loops. The transmit 
B1 field distributions for 1 W of accepted power were calcu-
lated as per Equation 5 and compared between the 13C (32.13 
MHz) and 23Na (33.79 MHz) frequencies.
The results are presented in a plane orthogonal to the 
B0 direction and averaged over a 100 mm slice.
2.5 | Multichannel coil noise correlation
Noise correlation was assessed using the 8-channel paddle re-
ceive coils in conjunction with the clamshell transmit. To acquire 
a noise-only scan, the RF amplifier was disabled, and multichan-
nel receive data was acquired at both 13C and 23Na frequencies.
2.6 | System magnetic field 
drift and 1H center frequency estimation from 
human studies
A retrospective analysis of previously acquired healthy 
(N = 8) and patient (N = 9) brain data acquired at site B 
between March 2016 and October 2018 was performed. 
Experiments were performed on a 3 T MR750 MR system 
(GE Healthcare) using a quadrature birdcage 13C/1H head 
coil (Rapid, Rimpar, Germany).
A phantom containing either approximately 8 mL of 
8 M 13C-urea or 1 M 13C-bicarbonate or 2 mL of 4 M [1-13C]
lactate was placed inside a disposable cover on the superior 
edge of the ear defenders for use during the calibration of 
frequency and pulse power, then generally removed prior to 
the hyperpolarized pyruvate injection.
Slice-selective 13C-MR spectra and/or images were ac-
quired from the brains of the 17 subjects following injection 
of 0.4 ml/kg of hyperpolarized [1-13C]pyruvate, as described 
previously.8 Slice-selection was performed using either a 
spectral–spatial pulse with a pass-band of 85 Hz (22.5 ms 
duration, or in most cases a partially self-refocusing sinc 
excitation as described above).11,23
Individual experimental parameters varied as the pro-
tocol developed. In in the majority of subjects, however, 
3 axial slices were collected (3 cm thick, 3 mm spacing) 
using the iterative decomposition using echo asymmetry 
and least squares estimation spiral CSI technique,12 with a 
cycle of 8 steps, including 1 slice-localized spectrum and 
7 single-shot spiral images with incremented echo time 
from which images were reconstructed at the frequency 
offsets for pyruvate, lactate, bicarbonate, alanine, and pyru-
vate hydrate. The usual temporal resolution of the dynamic 
acquisitions was 4 s (sequence repetition time 500 ms), 
excitation flip angle 15°, image FOV 24 cm, effective true 
resolution in-plane 12 mm, interpolated to 1.875 mm.
Spectra were analyzed in MatLab to measure the actual 
frequency of both 13C-pyruvate from the central brain slice in 
the time-averaged dynamic series and the reference standard 
during the preinjection calibration scan. The relationship was 
characterized between the actual 13C-pyruvate frequency in 
vivo and 3 different parameters, which could be used as a 
predictor of frequency (Temporal Drift, Phantom, and Water 
1H methods, described below). For each of these methods, 
a Bland-Altman analysis was performed comparing the 
pyruvate frequency predicted using that method and the true 
measured value for all subjects to retrospectively determine 
which method would have performed best.
1. Temporal Drift method. The frequency of pyruvate in 
vivo was assumed to vary in a slow linear fashion due 
to drift in the system B0. The transmit frequency for 
(5)B1 Difference =20 log
(
B
23Na
1
B
13C
1
)
.
F I G U R E  1  Schematic of the simulated model of the clamshell-type transmit coil with the hybrid circuit needed to excite the homogenous 
mode (C = 140 pF, L = 350 nH)
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a particular subject was therefore calculated from the 
slope of a linear fit to frequency against the date that 
the study was performed for all 17 subjects.
2. Phantom method. The frequency difference between 
pyruvate in vivo and the reference metabolite within the 
external phantom was tabulated, and the mean offset over 
all subjects was applied in each individual.
3. Water 1H method. The frequency of water in the 1H-MRI 
series immediately preceding the 13C experiment was re-
corded and divided by the ratio of the gyromagnetic ratio (γ) 
for 1H/13C (3.97595) to estimate the 13C frequency. The ad-
ditional offset of [1-13C]pyruvate from this frequency meas-
ured in vivo was tabulated, and the mean offset determined 
from all the subjects was applied in each individual.
2.7 | In vivo experiments using a 23Na and 1H prescan
A prospective study assessing the use of a 23Na and 1H prescan 
was performed at site A. Six female, Danish domestic pigs 
weighing ∼30 kg and fasted overnight were imaged. The pigs 
received intravenous propofol (12 mg initial dose; thereafter 
0.4 mg/kg/h for maintenance anesthesia) and intrave-
nous fentanyl (8 μg/kg/h) and were mechanically venti-
lated. Catheterization was performed through the femoral 
veins and arteries for the administration of hyperpolarized 
[1-13C]pyruvate and measurement of arterial blood pressure, 
respectively.
The pigs were imaged in a supine position, and the 
13C-receive loop was positioned centrally on the biceps fem-
oris muscle of the right lower limb. The receive coil and pig 
were placed in the central transmit field of the 13C-transmit 
coil. Bloch-Siegert experiments were performed prior to the 
13C-pyruvate injection for both the 23Na calibration acquisitions, 
with 1H center frequency taken from the previous series, and 
the 13C prescan acquired with 13C-lactate phantom. Frequency 
scaling between 1H/23Na and 1H/13C pyruvate was calculated 
from Equations 1 and 2, respectively. Approximately 24 mL of 
~250 mM hyperpolarized 13C-pyruvate was injected in the left 
femoral vein over 10 s, followed by a 20 mL saline flush. 13C 
magnetic resonance spectroscopy was performed at the com-
mencement of the 13C-pyruvate injection using the following 
parameters: partially self-refocusing sinc excitation,23 RF band-
width = 2000 Hz, spectral acquisition bandwidth = 5000 Hz, 
number of samples = 2048, repetition time = 1 s, time points = 
128, flip angle = 12°, and slice thickness = 40 mm.
2.8 | In vivo spectral postprocessing
Hyperpolarized spectra were fit using a matching pursuit 
algorithm, and apparent kinetic rate constants for the 
exchange of pyruvate to lactate (kPL) were calculated by 
solving the differential form of the modified Bloch equations 
in the time and frequency domains.24 Furthermore, spectra 
were summed in the complex domain over time, and [1-13C]
lactate:[1-13C]pyruvate and [13C]bicarbonate:[1-13C]pyru-
vate ratios were calculated. Ratiometric and kinetic data were 
averaged over all subjects.
2.9 | Statistical analysis
Statistical significance was defined as P < .05. The mean 
center frequency difference between 13C-urea and 23Na/1H at 
site A was determined by assessing the difference in center 
frequency between each paired 13C and 23Na and the 1H 
measurement and averaging the results. Using in vivo data 
from site A, the ratiometric frequency difference between 
hyperpolarized 13C-pyruvate and 1H/23Na across all porcine 
experiments was averaged.
Differences in RF gain between different saline loading states 
were assessed by fitting a linear model to the RF gain data.
Due to the small number of subjects used in this study, 
differences between time and frequency domain-derived ki-
netic parameters for the in vivo data were assessed using a 
Mann-Whitney U test.
3 |  RESULTS
3.1 | RF gain and f0 estimation using 23Na
The difference in 23Na (NaCl) and 13C (13C-urea) f0 at site 
A was 1664497 ± 12 Hz (mean ± standard deviation [SD]) 
with a mean scaling factor of 1.05180 ± 0.00001, as derived 
from Equation 1. The mean correction for the 23Na and 13C RF 
gain was 10.4 ± 0.6 dB, as derived from Equation 2. The cor-
relation between saline loading and RF gain, assessed using a 
linear model, found no significant results for any of the coil 
setups (R2 < 0.1 and P > .05 in all cases; loop and paddle coil 
results shown in Figure 2A,B, respectively). Because no sig-
nificant correlation between saline loading and RF gain was 
observed, data were averaged to estimate a mean RF gain dif-
ference between 13C and 23Na per coil experiment. Inspection 
of the calibration files for each coil demonstrated that there was 
a 1.35 dB difference in the additional requested system RF gain 
for the 13C loop and 8-channel paddles. The average RF gain 
for each coil setup is shown in Table 1, with expanded results 
in Tables 2 and 3.
3.2 | Multinuclear B1 and B0 mapping
13C and 23Na B0 maps showed a mean shift of +1 ± 18 Hz 
and −6 ± 23 Hz over the 6 × 6 CSI grid, respectively. 13C 
and 23Na B1 maps showed a similar RF distribution over the 
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FOV (Figure 3A-C). B1 maps showed a consistent small 
overflipping at both 23Na and 13C frequencies (1.14 ± 0.06 
and 1.18 ± 0.05, respectively). The absolute average differ-
ence between the B1 maps (Figure 4D) was 2 ± 6% over the 
FOV. Proton and original flip angle images can be seen in 
Supporting Information Figure S2.
3.3 | Transmit B1 simulations
The simulated transmit B1 profiles are shown in Figure 4A,B 
for the 13C and 23Na frequencies, respectively. The difference 
between the field maps calculated from Equation 5 is shown 
in Figure 4C, demonstrating that the field distributions are 
very similar for both frequencies, with the maximum differ-
ence throughout the phantom being less than 2 dB. In abso-
lute terms, the difference between the 13C and 23Na simulated 
field over the region of interest is 10.4 ± 0.2 dB, consistent 
with the experimental results.
3.4 | Multichannel coil noise correlation
Noise correlation between the 8 channels in the paddle 
coil revealed good linearity between coils, with little cor-
relation between channels from the off-diagonal elements 
F I G U R E  2  Differences in carbon-13 and sodium-23 RF gain required for a 90-degree excitation at varying sodium concentrations as 
measured with the loop (A) and paddle (B) coils using a Bloch-Siegert shift. The linear fit to the data and 95% confidence limits are shown.  
No significant correlations were found between the different loading states (R2 < 0.1 and P > .05 for all cases)
Coil 13C RF gain 23Na RF gain
Loop 14.7 ± 0.1 25.7 ± 0.1
Paddles 16.4 ± 0.1 27.4 ± 0.3
Results presented as mean ± SD.
T A B L E  1  Average results from RF 
gain over all saline loading conditions, per 
coil
Coil Phantom Concentration Nucleus RF gain (dB) SD (dB)
Paddles 156 mmolL−1 23 27.3 0.2
    13 17.4 1.1
  112 mmolL−1 23 27.6 0.2
    13 17.4 0.3
  75 mmolL−1 23 27.4 0.5
    13 17.7 0.3
  50 mmolL−1 23 27.6 0.3
    13 18.2 0.8
Results presented mean ± SD.
T A B L E  2  TG for all saline loading 
conditions for both the paddle coil
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(Figure 5A). However, when performing at the 23Na fre-
quency, there was substantial off-diagonal coupling be-
tween elements (>0.6), as demonstrated in Figure 5B.
3.5 | System magnetic field drift and 1H center frequency estimation from in 
man studies
3.5.1 | Temporal drift method
The site B frequencies of both pyruvate in vivo and urea in the 
phantom drifted slowly downward over the 31-month time-
scale of the experiments (Figure 6). The rate of drift calculated 
from a linear fit to the pyruvate frequencies was 0.36 Hz/day. 
This drift is small in comparison to the scanner specification 
limits, which allow for drifts of up to 0.1 ppm/h, although 
such large drifts would only be expected in the case of heat-
ing due to running sequences with a high gradient duty cycle. 
An upgrade to the scanner software but using the existing 
hardware occurred in December 2017; however, this induced 
no discernible step change in frequency. Frequency shifts of 
T A B L E  3  TG for all saline loading conditions for the loop coil
Coil
Phantom 
Concentration Nucleus
RF 
gain (dB) SD (dB)
Loop 156 mmolL−1 23 25.7 0.1
    13 14.7 0.1
  112 mmolL−1 23 25.8 0.2
    13 14.6 0.1
  75 mmolL−1 23 25.6 0.1
    13 14.6 0.1
  50 mmolL−1 23 25.8 0.2
    13 14.7 0.1
Results presented mean ± SD.
F I G U R E  3  Simulated transmit B1 field distributions for the transmit volume coil used in this study. Transmit B1 distribution at 13C (32.13 
MHz) and 23Na (33.79 MHz) frequencies (A and B, respectively). (C) Ratio between required power for 90-degree flip for 13C and 23Na frequencies 
for the same coil. The phantom position is highlighted with a white line
F I G U R E  4  (A) Chemical shift image grid overlaid on an 8 L phantom containing 150 mmolL−1 NaCl and 102 mmolL−1 13C-pyruvate.  
(B and C) 13C and 23Na transmit B1 maps, respectively. (D) Ratiometric difference maps between B and C
8 |   GRIST eT al.
other metabolites in vivo relative to pyruvate appeared very 
consistent.
3.5.2 | Phantom method
The difference between the frequencies of 13C-pyruvate in 
vivo and 13C-urea in the phantom varied over a wide range 
(186 ± 43 Hz). The frequency separation was not correlated 
with date of acquisition (R2 = 0.05), suggesting it was un-
likely to be due to phantom degradation.
3.5.3 | Water 1H method
The 1H frequency of water scaled to the 13C frequency by the 
respective gyromagnetic ratios, as described above, was on 
average 2620 ± 11 Hz higher than the pyruvate frequency 
in vivo.
Frequency prediction using the temporal drift or by ref-
erencing to the external phantom both performed poorly 
(Figure 7): the SD of differences (predicted minus ac-
tual) was 39 and 40 Hz, respectively, and 5 or 6 subjects, 
respectively, would have been outside the bandwidth of 
spectral–spatial excitation (error > 40 Hz) in the cohort of 
17. Frequency prediction based on the water 1H frequency 
performed better, with a SD of only 11 Hz, and there were 
no subjects in whom spectral–spatial excitation would have 
failed. All results are shown in Figure 7.
3.6 | In vivo experiments
Prospectively utilizing the 23Na and 1H prescan, hyperpo-
larized 13C-magnetic resonance spectroscopy was success-
fully performed from the musculature of 6 pigs following 
the injection of hyperpolarized 13C-pyruvate signal from 
13C-pyruvate, 13C-lactate, and 13C-bicarbonate observed in 
F I G U R E  5  Coupling of coil channels for 8-channel paddle coils at the carbon-13 (A) and sodium-23 (B) frequencies demonstrating increased 
coupling for the 23Na frequency
F I G U R E  6  Measured frequency 
(+32130000 Hz) of 13C-pyruvate (pyruvate) 
in vivo and 13C-urea in vitro for all human 
brain hyperpolarization studies at site B over 
a 31-month period
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all subjects. The frequency scaling between 23Na/13C and 
13C/1H calculated using Equations 1 and 2 was 1.05179 ± 
0.00001 (mean ± 1 SD) and 3.97630 ± 0.00001 (mean ± 
1 SD), respectively. The mean 13C and 23Na RF gain was 
156 ± 2 and 260 ± 3, respectively. Kinetic analysis revealed 
a mean kPL of 0.007 ± 0.002 and 0.007 ± 0.002 s−1 in the fre-
quency and time domains, respectively, with no significant 
difference between methods (P > .05). The correlation (R2) 
between kPL in the frequency domain and lactate:pyruvate 
ratio was 0.9 with P = .01.
The mean [1-13C]lactate:[1-13C]pyruvate (LAC/PYR) and 
[13C]bicarbonate:[1-13C]pyruvate (BIC/PYR) ratios were 
0.15 ± 0.04 and 0.006 ± 0.004, respectively.
4 |  DISCUSSION
Hyperpolarized 13C-MRI is a powerful technique to noninva-
sively probe tissue metabolism in many normal and diseased 
tissues, such as brain, heart, kidneys, and cancer.4,8,25-27 For 
example, increased lactate signal has been shown to correlate 
with more aggressive tumors, and a reduction in this lactate 
is seen in a wide range of tumor models following treat-
ment.28-30 This work is now being translated into humans, 
and early clinical research has shown elevated hyperpolar-
ized 13C-lactate in prostate cancer as well as in brain and 
breast tumors. Clinical hyperpolarized 13C studies face a 
number of technical challenges, including accurate frequency 
calibration and the requirement for system inhomogeneity 
correction. This is particularly problematic due to the low 
natural abundance of 13C in tissue, which results in poor sig-
nal from endogenous 13C nuclei, and which in turn renders 
the determination of the center frequency and TG difficult. 
Therefore, new approaches are needed to increase confidence 
in 13C prescan results, estimation of RF gain, transmission of 
B1 distribution, and other coil sensitivity parameters.
Here, we show that the center 13C frequency can be ac-
curately estimated using the water 1H frequency, which per-
formed better than 2 alternative approaches that we explored: 
frequency drift and using an external 13C-urea phantom. In 
addition, we have recently shown the feasibility of using a 
13C-tuned coil to image the distribution of 23Na in tissue due 
to the high natural abundance of the latter and the small fre-
quency difference between the 2 nuclei.16 Here, we have ex-
plored whether this 23Na signal could also be used to improve 
13C-MRI acquisition. The results show that the RF gain and 
f0 for 13C can be estimated using the endogenous 23Na reso-
nance acquired using dedicated, commercially available and 
clinical 13C-coils.
There are additional benefits in utilizing the 23Na reso-
nance to calibrate the 13C experiments: the short T2 and T1 of 
the nucleus allow rapid data averaging to increase signal to 
noise ratio and thus increase the confidence in the calibration 
parameters. Conversely, the long T1 of 13C-labeled molecules 
(on the order of several s) can lead to lengthy acquisition 
times for calibration, which further compound the problems 
of the low natural abundance of the nucleus.
Here, we have demonstrated the potential for using the 
1H and 23Na resonances to provide a robust prescan for 
hyperpolarized 13C experiments, with center frequency 
and RF gain, for single and multichannel clinical coils. 
Simulations showed consistent overflipping at 13C fre-
quency by the clamshell, which was also experimentally 
observed. The simulated field 23Na frequency was highly 
homogeneous, which was also experimentally observed 
in the B1 maps. Therefore, this provides a commercially 
available solution to the prescan and calibration required 
for 13C-MRI and could assist in simplifying hyperpolarized 
F I G U R E  7  Difference between the predicted and measured frequency (+32130000 Hz) of 13C-pyruvate in vivo from human brain 13C-MRI 
studies at site B using the 3 approaches presented here. Circles: 13C frequency prediction from a linear fit to the study date, accounting for a drift of 
0.36 Hz/day. Triangles: 13C frequency prediction by adding the mean offset between phantom and pyruvate to the phantom frequency. Squares:  
13C frequency prediction based on the 1H frequency of water acquired from the anatomic series
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13C-MRI acquisition. In the future, multislice B1 maps 
with ultrashort echo time sequences could be acquired to 
complement current human imaging protocols, providing 
a slice-by-slice correction for transmit B1 for further quan-
titation. However, this will require further experimental 
optimization (acquisition of coil sensitivity maps, optimal 
trajectory design, and eddy current compensation) before 
clinical implementation is achieved.31,32 Indeed, bolus 
tracking methods have been developed to calibrate using 
the hyperpolarized signal, providing real-time calibration 
for selective excitation experiments.33 These techniques 
are promising and provide an alternative approach to the 
method presented here. A challenge for the implementa-
tion of these methods in vivo is that they commonly require 
significant scanner modifications to allow for third-party 
software control of the clinical system.34 Given that our 
results have also shown significant changes in acquisition 
parameters over time, leading to temporal alterations in the 
center frequency for 1H and 13C-pyruvate, it is advisable 
to utilize the 23Na or 1H prescan before each experiment 
rather than assuming a static center frequency because se-
lective excitation strategies may otherwise fail.
A challenge to our proposed method is the coupling be-
tween multichannel 13C coils, which significantly increased 
at the 23Na frequency. This could represent a problem for 
estimation of the sensitivity maps using array coils, but future 
13C coil design could ensure that this effect is minimized. Future 
studies could assess this concept in human experiments, in-
cluding a comparison of kPL values before and after correction 
with a sodium B1 map. Uncertainty in transmit B1 dramatically 
increases the error in kinetic modeling, which could have sig-
nificant implications for the interpretation of the results as part 
of clinical trials.10 Interestingly, there appeared to be a differ-
ence in the RF gain required for the 8-channel paddle coils and 
the single loop coil used in this study, with an approximate 
difference of 2 dB. This difference is partially due to the dif-
ference in vendor coil files (1.35 dB), and we hypothesize that 
the remainder is due to differences in coil positioning and vol-
umetric coverage because the transmit clamshell has a nonuni-
form transmit field (Figure 4). Further differences in TG could 
be found in variations in coil matching at the 23Na frequency, 
leading to differences in TG required for a 90-degree exci-
tation. Reductions in transmit efficiency are expected when 
operating away from the intended frequency due to degrada-
tion in the quality of the tune and match of the coil, although 
the relatively small difference in TG needed here suggests this 
degradation is not severe. In the future, the TG could also be 
used to indirectly inform on the quality of the tune and match. 
Although we have demonstrated here that 13C coils can be suc-
cessfully used to measure the 23Na resonance, this approach 
should be applied with caution by assessing the coil response 
at both frequencies on the bench and also by undertaking stud-
ies in phantoms prior to performing these studies in humans.35
5 |  CONCLUSION
We have demonstrated the feasibility of using the 23Na and 
1H resonances to calibrate the 13C transmit B1 using com-
mercially available 13C-coils. The method provides a simple 
approach for in vivo calibration and could improve clinical 
workflow.
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SUPPORTING INFORMATION
Additional Supporting Information may be found online in 
the Supporting Information section.
FIGURE S1 Phantom setup. Saline filled buckets 
(150 mmolL−1, 1 L) with the 8-channel paddle coils (A) or 
the single loop coil (B) inside the clamshell transmit coil. The 
black arrow points to the 13C enriched urea phantom
FIGURE S2 Individual 1H (A) and x-nuclei flip angle im-
ages for 23Na (B and C, 40 and 80 degrees, respectively) and 
13C (D and E, 40 and 80 degrees, respectively) acquired from 
an 8 L phantom. 23Na and 13C images are normalized to the 
largest signal in their 80-degree images
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